GlucoTrack, Inc. - GCTK STOCK NEWS

Welcome to our dedicated page for GlucoTrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on GlucoTrack stock.

GlucoTrack, Inc. (symbol: GCTK) is a pioneering medical device company focused on the innovation and commercialization of non-invasive glucose monitoring devices. Established in 2001, the company aims to improve the quality of life for individuals with diabetes by eliminating the pain and inconvenience associated with traditional glucose monitoring methods. Since its inception, GlucoTrack has been dedicated to developing breakthrough technologies that provide a seamless glucose monitoring experience.

The company’s flagship product, the GlucoTrack® model DF-F, utilizes a unique combination of ultrasound, thermal, and electromagnetic technologies along with a proprietary algorithm to measure glucose levels without the need for painful finger pricks. This device has received CE Mark approval in June 2013 and KFDA approval in March 2016. Currently, the GlucoTrack® model DF-F is marketed across the European Union and South Korea.

In November 2011, GlucoTrack went public, further broadening its scope and capabilities in the medical device industry. The company has completed a successful feasibility study indicating that the non-invasive sensor design has a minimum two-year implant life. An ongoing animal study with an initial prototype system has also shown promising results, demonstrating a straightforward implant procedure and effective functionality.

GlucoTrack, Inc. continues to focus on enhancing its product offerings and expanding its market presence through strategic partnerships and continuous innovation. For the latest updates and information about GlucoTrack, visit the company’s official website or contact their investor relations team at: investors@glucotrack.com.